Literature DB >> 9625439

Prolonged remission of endometrial cancer with paclitaxel and carboplatin.

A Vasuratna1, A P Kudelka, C L Edwards, V Wootipoom, C F Verschraegen, C Charnsangavej, J J Kavanagh.   

Abstract

Recurrent endometrial cancer has grave prognosis. Chemotherapy and hormonal therapy are mainstays of palliative treatment. Unfortunately the frequency of complete response and duration of progression-free interval are limited. This case report describes a patient with recurrent metastatic endometrial cancer who was initially treated with radiotherapy followed by surgery. Her recurrent tumor progressed during treatment with external radiation and a progestogen. She received paclitaxel (135 mg/m2 i.v. infusion over 24 h) and carboplatin (AUC 7.5 microg x h/ml) every 4 weeks with complete remission after 8 months which has persisted for 22 months. Paclitaxel and carboplatin combination should be considered for the treatment of endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9625439     DOI: 10.1097/00001813-199803000-00011

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  4 in total

1.  Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.

Authors:  Chad M Michener; Gertrude Peterson; Barbara Kulp; Kenneth D Webster; Maurie Markman
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

2.  Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.

Authors:  Tadao Takano; Takeo Otsuki; Hideki Tokunaga; Masafumi Toyoshima; Hiroki Utsunomiya; Satoru Nagase; Hitoshi Niikura; Kiyoshi Ito; Nobuo Yaegashi; Hidekazu Yamada; Toru Tase; Masahiro Kagabu; Tadahiro Shoji; Toru Sugiyama; Naoki Sato; Toshio Fujimoto; Yukihiro Terada; Kenji Nakahara; Hirohisa Kurachi; Yoshihito Yokoyama; Hideki Mizunuma; Shu Soeda; Hiroshi Nishiyama; Takashi Matsumoto; Shinya Sato; Muneaki Shimada; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2014-01-07       Impact factor: 3.402

Review 3.  Systemic therapy for advanced or recurrent endometrial carcinoma.

Authors:  G F Fleming
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

Review 4.  New developments and approaches in the platinum arena.

Authors:  I Judson; L R Kelland
Journal:  Drugs       Date:  2000       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.